Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Recurrence 2Ovarian Neoplasms 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Lymphoma, Mantle-Cell 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Skin Neoplasms 1Prostatic Neoplasms 1Neoplasm Metastasis 1Myeloid Malignancy 1Melanoma 1MDS 1Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Esophageal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Rituximab 226Cyclophosphamide 202fludarabine phosphate 108Peripheral Blood Stem Cell Transplantation 103Filgrastim 87Etoposide 76Cytarabine 70ibrutinib 68Mycophenolic Acid 67Bortezomib 66Whole-Body Irradiation 63Cyclosporine 63Melphalan 59Lenalidomide 59Bendamustine Hydrochloride 58Vincristine 53Radiotherapy 53fludarabine 52Tacrolimus 50Doxorubicin 48Busulfan 48Methotrexate 47Antilymphocyte Serum 42Prednisone 41Carmustine 40Dexamethasone 38Granulocyte Colony-Stimulating Factor 33venetoclax 32acalabrutinib 31zanubrutinib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, Mantle-Cell × eprenetapopt × Clear all
NCT04419389 2025-03-17

R/R

Aprea Therapeutics

Phase 1/2 Terminated
1 enrolled 4 charts
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT04990778 2022-03-10

Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡